Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic

preview_player
Показать описание
Join two haematologic oncologists as they answer questions about optimizing the use of JAK inhibitors for patients with myelofibrosis.

Featuring insights from Prof. John Mascarenhas and Dr Raajit Rampal.

This previously live event is now available on demand!

--------
This activity is funded by an independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.
  1. Touch Medical Media
Рекомендации по теме
Optimizing outcomes of 0:12:34

Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic

How to Manage 0:25:15

How to Manage Side Effects of JAK Inhibitors for Mylofibrosis in the Clinical Practice

Survival benefit of 0:14:28

Survival benefit of JAK inhibition in MF: JAK inhibitor for all MF patients?

Why can JAK 0:01:22

Why can JAK inhibitors cause weight gain?

The role of 0:15:32

The role of JAK inhibitors in your clinical practice

An overview of 0:28:40

An overview of selective Jak inhibitors and relevance for SJIA-LD - Dr. Massimo Gadina

Improving Outcomes for 0:45:08

Improving Outcomes for Patients With Refractory Rheumatoid Arthritis

JAK Inhibitors in 0:26:03

JAK Inhibitors in Rheumatoid Arthritis

How to Manage 0:58:48

How to Manage JAK Inhibition in Patients Undergoing HCT

JAK inhibitors for 0:26:43

JAK inhibitors for IBD

Dr. Bose on 0:12:48

Dr. Bose on JAK Inhibitor Optimization, Trial Updates in Myelofibrosis

Optimizing outcomes in 0:02:37

Optimizing outcomes in patients with cancer cachexia

My view on 0:19:04

My view on current and future use of JAK inhibitors for ET, PV, and MF

John Koo, MD 0:01:11

John Koo, MD - Are topical JAK inhibitors, on the whole, more efficacious than superpotent topical..

Improving Transfusion Independence 0:05:00

Improving Transfusion Independence With JAK Inhibitor Therapy

Investigating the place 0:00:53

Investigating the place of JAK inhibitors in the treatment of myelofibrosis

Insights at EULAR 0:45:12

Insights at EULAR 2020: Clinical Data on JAK Inhibitors

Managing Treatment-Related Toxicities 0:05:30

Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

Dr Amanam on 0:01:28

Dr Amanam on the Management of AEs Associated With JAK Inhibitors in Myelofibrosis

Management of Myelofibrosis: 1:03:11

Management of Myelofibrosis: JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

Forum LIVE: JAK 0:54:10

Forum LIVE: JAK Inhibitors in PsA

Ruxolitinib and JAK 0:01:53

Ruxolitinib and JAK inhibitors prior to transplantation

Leveraging JAK Inhibitors 0:20:57

Leveraging JAK Inhibitors in Ulcerative Colitis: Strategies for the IBD Management Team

Optimizing current treatment 0:02:33

Optimizing current treatment approaches in myelofibrosis